Bayer
German multinational pharmaceutical, chemical, and agricultural biotechnology company
Positive
Negative
Entity sentiment
Reports
News
Opinions
Statements
Articles
Relations
business Feb 18, 2026, 9:50 AM
Bayer proposes $7.25 billion settlement to address Roundup cancer lawsuits - Bayer proposes a $7.25 billion settlement to address thousands of lawsuits related to its Roundup herbicide, claiming it caused cancer.
- This plan is aimed at mitigating ongoing legal challenges and will increase litigation reserves to nearly $12 billion.
- The settlement requires judicial approval and adequate participation from plaintiffs, highlighting Bayer's strategy for managing legal risks and financial stability.
100
business Feb 18, 2026, 1:00 AM
Bayer proposes $7.25 billion settlement amid Roundup cancer lawsuits - Bayer has filed a proposed $7.25 billion settlement for 200,000 claims related to Roundup causing cancer.
- The settlement aims to provide financial relief while the U.S. Supreme Court considers whether the EPA's approval can invalidate claims.
- Bayer's CEO views this settlement as a pathway to closure amid ongoing litigation uncertainties.
100
business Feb 17, 2026, 9:13 PM
Bayer proposes $7.25 billion settlement for Roundup cancer claims - Bayer has faced significant lawsuits related to its Roundup weedkiller, which has been associated with non-Hodgkin lymphoma.
- The company proposes a $7.25 billion settlement that includes future claims and will disperse payments over 21 years.
- This settlement aims to provide closure for Bayer amid ongoing legal challenges and financial burdens.
100
business Feb 17, 2026, 8:16 PM
Bayer proposes $7.25 billion settlement to resolve Roundup cancer lawsuits - Bayer has announced a proposed settlement of $7.25 billion to resolve lawsuits related to Roundup.
- The settlement aims to alleviate ongoing legal uncertainties regarding the product's safety and associated cancer claims.
- This move may provide closure for both the company and individuals affected by the litigation.
100
2026 All rights reserved
2026 All rights reserved